Conditional modeling of antibody titers using a zero-inflated poisson random effects model: Application to Fabrazyme®

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 5, 2009, Pages 443-459

  Bonate, Peter L ^a   Sung, Crystal ^b   Welch, Karen ^b   Richards, Susan ^b  

^a GLAXOSMITHKLINE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Hurdle model; Mixed effects; NLMIXED; Nonlinear mixed effects models; Seroconversion; Zero inflated negative binomial

Indexed keywords

AGALSIDASE BETA; IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINOMIAL DISTRIBUTION; CHILD; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; FABRY DISEASE; GEOMETRY; HALF LIFE TIME; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; SCHOOL CHILD; SEROCONVERSION; STATISTICAL MODEL; STEADY STATE; STRUCTURAL EQUATION MODELING; ZERO INFLATED PIOSSON RANDOM EFFECTS MODEL;

ADOLESCENT; ALGORITHMS; ALPHA-GALACTOSIDASE; ANTIBODIES; ANTIBODY FORMATION; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FABRY DISEASE; HALF-LIFE; HUMANS; ISOENZYMES; MALE; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; POISSON DISTRIBUTION; PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 70350564360     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9132-x     Document Type: Article

References (8)

1. MHV van Regenmortel K Boven F Bader 2005 Immunogenicity of biopharmaceuticals: an example from erythropoetin BioPharm Int 18 36 50
2. H Schellekens 2002 Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Dis 1 457 462 10.1038/nrd818 1:CAS:528:DC%2BD38Xkt1Cmur8%3D
3. SM Richards 2002 Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders Clin Appl Immunol Rev 2 241 253 10.1016/S1529-1049(02)00049-1 1:CAS:528:DC%2BD38XnvVGrtrg%3D (Pubitemid 35439108)
4. Cameron AC, Trivedi PK (1998) Regression analysis of count data. Cambridge University Press, Cambridge
5. CE Rose SW Martin KA Wannemuehler BD Plikaytis 2006 On the use of zero-inflated and Hurdle models for modeling vaccine adverse event count data J Biopharm Stat 16 463 481 10.1080/10543400600719384 1:STN:280: DC%2BD28vmvFGgug%3D%3D 16892908 (Pubitemid 43995556)
6. F Kianifard PP Gallo 1995 Poisson regression analysis in clinical research J Biopharm Stat 5 115 129 10.1080/10543409508835101 1:STN:280:DyaK2MzjvVahsQ%3D%3D 7613557
7. WR Wilcox M Banikazemi N Guffon S Waldek P Lee GE Linthorst RJ Desnick DP Germain for the International Fabry Disease Study Group 2004 Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Am J Hum Genet 75 65 74 10.1086/422366 1:CAS:528:DC%2BD2cXltFClsrc%3D 15154115
8. F Corbiere P Joly 2007 A SAS macro for parametric and semiparametric mixture cure models Comput Methods Programs Biomed 85 173 180 10.1016/j.cmpb.2006.10.008 17157948 (Pubitemid 46108129)